Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-399P (RNA, U6 small nuclear 399, pseudogene) is a pseudogene, meaning it represents a nonfunctional segment of DNA that bears strong sequence similarity to the genuine U6 small nuclear RNA (snRNA) gene family but does not encode a functional product[2][7]. Pseudogenes like RNU6-399P are typically the result of gene duplication or retrotransposition events, and they are classified as "processed" or "unprocessed" depending on their genomic features[6]. Unlike the canonical U6 snRNA, which is an integral, functional RNA component of the spliceosome complex required for pre-mRNA splicing in eukaryotic cells[1][3], pseudogenes such as RNU6-399P lack the regulatory elements or sequence integrity required for transcription into a functional RNA. There is no evidence that RNU6-399P serves as a protein-coding gene, functional RNA, drug target, or has direct biological, pathological, or clinical significance[2][7]. The presence of U6 snRNA pseudogenes is common in vertebrate genomes and reflects evolutionary gene duplication and genome complexity[3][5][6]. Key points: - RNU6-399P is a pseudogene related to U6 snRNA. - It does not encode a functional RNA or protein, nor does it play a direct role in cellular function or disease[2][7]. - It is not considered a therapeutic target. - There are no known clinical or pharmacological implications. - The entry may be considered “incorrect” for therapeutic or target-focused applications, as it is nonfunctional and lacks biological activity[2][7]. If you were seeking information about the functional U6 snRNA: - The canonical functional gene is called "U6 small nuclear RNA" (often abbreviated as "RNU6" or "U6 snRNA"). - U6 snRNA is critical for splicing and spliceosome assembly, but RNU6-399P is only a nonfunctional, genomic byproduct related to this family[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 399, pseudogene (RNU6-399P).